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a b s t r a c t
27Organometallic catalysis has allowed the development of an impressive number of chemical transforma-
28tions that could not be achieved using classical methodologies. Most of these reactions have been accom-
29plished in organic solvents, and in many cases in the absence of water, and under air-free conditions. The
30increasing pressure to develop more sustainable transformations has stimulated the discovery of metal-
31catalyzed reactions that can take place in water. A particularly attractive extension of this chemistry con-
32sists of the use of biological relevant aqueous solvents, as this might set the basis to translate catalytic
33metal complexes to biological settings. While this research field is in its infancy, along the last ten years
34there have been an increasing number of reports demonstrating the viability of achieving metal-
35promoted transformations in biologically relevant contexts. In this review, that does not intend to be
36comprehensive, we summarize the most significant advances in the area, and highlight some of the more
37important difficulties that must be faced when trying to design biocompatible organometallic catalysts,
38such us stability, cell uptake, bioorthogonality and toxicity. We will manly focus on transition metal sys-
39tems which have been showed to keep their activity in complex aqueous buffers and inside living cells.
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66 Organometallic catalysis in water is itself a quite new field of
67 research which has been mainly developed within the context of
68 ‘‘Green chemistry” [1–6]. In recent years, there have been many
69 reports on metal-catalyzed reactions that can take place in water,
70 including couplings, isomerizations, cyclizations, cycloadditions
71 or hydrolysis processes. Despite this progress, the number of
72 water-compatible organometallic reactions is still very small when
73 compared with transformations achieved in organic solvents [7,8].
74 Thus, one should expect many new contributions in the coming
75 years.
76 Given that the basic solvent of biological habitats is water, it is
77 not difficult to envision that some of these transformations might
78 be achieved in bio-relevant media. However, the complexity of bio-
79 logical solvents, owing to the presence of a high concentration of
80 biomolecules such as thiols or amines which can poison the metal
81 and kill the catalytic activity, makes extremely challenging to
82 translate metal-catalyzed reactions to such media. Even more dif-
83 ficult is the transfer to living cells, as in this case additional issues
84 such as cell uptake and transport, and especially, side biological
85 activities [9–12], need to be taken into account. In addition, transi-
86 tion metal speciation should be considered, as this could influence
87 the reactivity as well as the toxicity of the metals [13,14]; however,
88 studies in this area, in the context of metal-promoted reactions in
89 cell culture, are yet lacking. Anyhow, in recent years there have
90 been many reports on the use of metal complexes in complex
91 aqueous buffers, and even in vivo settings [15–18]. While
92 organometallic catalysis in biological media is yet an emerging
93discipline, it seems clear that being able to achieve non-natural
94catalytic transformations of exogenous substrates in bio-settings
95might unleash a new world of opportunities for biological and
96medicinal research. This can be of great relevance for instance for
97the in situ generation of drugs, the amplification of optical signals
98for the detection of biomarkers, or the metal-promoted modifica-
99tion of biomolecules, among others.
100Undoubtedly, one of the key discoveries that has had a more
101significant impact on the development of biocompatible metal-
102catalyzed transformations was the report by Sharpless and by Mel-
103dal on the famous Copper-Catalyzed Azide–Alkyne Cycloadditions
104(CuAAC, Scheme 1) [19,20]. This reaction has changed our capabil-
105ity to transform and monitor biomolecules, in some cases even in
106living atmospheres, in the presence of many other native molecu-
107lar components. This type of reactions belongs to what Bertozzi
108coined as Bioorthogonal Chemistry [21,22]. The copper-promoted
109annulations can be considered as the first metal-catalyzed reac-
110tions that could be achieved in complex aqueous media and even
111in cell culture media for the modification of cell surface sugars
112[23–25] and proteins [26]. The cytotoxicity of Cu(I) ions, however,
113has significantly hindered the application of this reaction in the
114internal space of living cells.
115After these ground-breaking and inspiring developments in
116bioorthogonal chemistry, other research groups started to investi-
117gate the applicability of other metals to this new field of research.
118Nevertheless, moving to cells is not trivial, as the living cell is a
119very complex, compartmentalized and dynamic entity, with a very
120high concentration of biomolecules, including thiols. Despite this,
121recent data suggest that certain transition metal derivatives can
Scheme 1. Initial mechanism proposed by Sharpless for the CuAAC [19].
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122 promote intracellular reactions through typical organometallic
123 mechanisms. Here, we have to remark the pioneering work by
124 Streu and Meggers on the development of Ru(II) catalysts compat-
125 ible with living cells [27], and by Bradley and co-workers [28] and
126 Chen and co-workers [29] on the development of Pd based sys-
127 tems. In this review, we will summarize some key developments
128 in the field, paying special attention to Ru and Pd compounds;
129 but we will also discuss some achievements with other metals.
130 At the end of the review we will also briefly comment on recent
131 developments on the preparation of artificial metalloenzymes.
132 This field of research is young, but steadily growing, and a num-
133 ber of reviews dealing with transition metal catalysis in biological
134 settings [30–33], bioorthogonal protein modifications [34] and
135 artificial metalloenzymes [35–40], have been already published.
136 While the above reviews on metal-promoted reactions in bio-
137 logical media are either classified by reaction types, or centered
138 on biopolymer modifications, or on specific metals, we use an orga-
139 nization based on the type of metals. This is particularly illustrative
140 because it gives a comparative idea of the transformative possibil-
141 ities offered by each of them, and their potential for future
142 applications.
143 Finally, it is important to note that while in some sentences we
144 might write ‘‘metal catalysis”, in most of the examples with living
145 systems, turnover has not yet been fully demonstrated.
146 2. Transition metal catalysis in biologically settings
147 2.1. Ruthenium
148 Organometallic ruthenium complexes have been widely consid-
149 ered in bioinorganic chemistry, especially because of their anti-
150 cancer potential [41]. Even some of them have shown relevant
151biological activities owing to their intracellular catalytic activities,
152for instance by interfering with the balance of GSH and NAD/
153NADH, which leads to cell death [42,43]. Ruthenium complexes
154have been widely used in catalytic organometallic chemistry, and
155therefore translating some of these reactions to biological settings
156is highly promising. The use of Ru(II) organometallic complexes as
157catalytic promoters of exogenous transformations in cellular set-
158ting started with a seminal report by Streu and Meggers in 2006,
159that demonstrated the viability of achieving a metal promoted
160release allylcarbamate-protecting groups in the interior of HeLa
161cells (Fig. 1) [27]. For monitoring the reaction, they used as sub-
162strate a bis-allylcarbamate caged rhodamine 110 (1) which was
163virtually non-fluorescent. The uncaging of this molecule gives rise
164to rhodamine 110 (2) which emits green light upon excitation. The
165reaction was carried out using [RuCp⁄(COD)Cl] (3) as catalyst
166(Fig. 2). They first carried out an in vitro exploration of the best con-
167ditions to achieve a Ru-promoted cleavage of the allylcarbamate
168group (alloc) of a protected p-methylaniline, under a variety of
169aqueous buffers, finding that the reaction is better achieved in
170the presence of nucleophilic thiols.
171They then moved to living HeLa Cells, observing that when the
172cells were pre-incubated with 1 (100 lM) for 30 min, washed with
173PBS buffer solution, and then treated with the ruthenium complex
1743 (20 lM) and thiophenol (PhSH) (500 lM), there is an increase in
175green light emission due to the release of 2 (Fig. 1). A few years
176later, the same authors carried out a similar deprotection reaction
177using another Ru(II) organometallic precursor [RuCp⁄(g6-pyrene)]
178PF6 (4, Fig. 2), that can be activated (detachment of the pyrene
179ligand) by irradiation with light (k = 330 nm). As in the case of 3,
180the reaction with 4 also needed the presence of PhSH as additive
181[44]. The next contribution in this area was achieved by the group
182of Mascareñas et al., who demonstrated that is possible to use the
Fig. 1. (a) Representation of the uncaging of 1 promoted by RuCp*(COD)Cl (3) and (b) imaging of HeLa cells: (i) before the addition of the Ru catalyst to cells preincubated with
1, and PhSH and (ii) 15 min after the addition of ruthenium complex 3. (b) Adapted by permission [27]. Copyright 2006, Wiley-VCH.
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183 Ru-promoted reaction to activate DNA binders like 40,6-Diamidine-
184 20-phenylindole (DAPI), Ethidium bromide (EtBr) and bisbenza-
185 midines [45], inside living mammalian cells, by removing inacti-
186 vating alloc protecting groups from their protected precursors
187(DAPI-alloc (10), bisbenzamidines-alloc (11b) and EtBr-alloc (12)
188(Fig. 3) [46]. The authors carried out several control experiments
189that were consistent with the reaction taking place inside mam-
190malian cells. These results set the stage for future developments
Fig. 2. Structure of ruthenium complexes used as catalysts inside cells. (a) 3 [27] and 4 [44]; (b) Kitamura’s derived Ru(IV) catalysts 5a–c employed by Meggers et al. [49]; (c)
catalysts 6–8 synthetized by Mascareñas et al., in the study of mitochondrial specific catalysis [51] and (d) second generation of quinoline derived Ru(IV) catalyst (9) reported
by Meggers et al. [53].
Fig. 3. (a–c) Schematic representation of caged DNA binders; (d) imaging of cells treated with (i) EtBr–alloc (green channel) (12) and (ii) same cells after the addition the
ruthenium complex 3 and PhSH, where it can be observed how after the removal of the alloc groups, the initial green light turns into the red light emission of EtBr (red
channel) [46].
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191 on metal-promoted activation of DNA-binding compounds in bio-
192 logical media.
193 The above uncaging strategies employing Ru(II)Cp⁄ complexes
194 required the use of relatively large amounts of PhSH as an external
195 nucleophile to ensure turnover, a compound that is toxic to the
196 cells. This problem has been recently solved by Volker and Meggers
197 by using ruthenium(IV) catalysts with quinoline ligands that had
198 been previously described by Kitamura et al., for the catalytic
199 dehydrative allylation of alcohols (Fig. 2b) [47,48]. With these
200 organoruthenium complexes (5, Fig. 2), it was possible to use
201 weaker nucleophiles than PhSH such as glutathione (GSH), which
202 is already present in relatively large amounts inside cells. The
203 authors have proposed the catalytic cycle indicated in the Scheme 2
204 for the uncaging of alloc protected amines [49].
205 These catalysts were more active than ruthenium complex 3,
206 greatly increasing the turnover number (TON) of the reaction,
207 which could be further modulated by changing the substitution
208 of the position 4 of the quinoline ligand. Thus, the presence of a
209 donor atom at this position increased the catalytic performance
210 (5b, 5c, Fig. 2). Importantly, this type of catalysts can be used in
211 the presence of living mammalian cells without the need to add
212 PhSH as additive, since glutathione (GSH), which is already present
213 in the cells, acts as nucleophile (NuH) to close the Ru–p–allyl cat-
214 alytic cycle.
215 Despite all data suggested that the Ru-catalyzed uncaging is
216 highly effective in the presence of living cells, the intracellular nat-
217 ure of the process was not unambiguously demonstrated.
218 Noticeable, a paper published by Waymouth and Wender in
219 2016 using 4T1 cells, suggested that these Ru(IV) complexes are
220 readily washed out with phosphate buffered saline (PBS), and
221 raised doubts on whether the above deallylation reactions is intra-
222 cellular. In these experiments they describe the removal of an alloc
223caging group in a luciferase substrate, which allowed for analyzing
224the cellular reactivity by measuring fluorescent outputs [50].
225More recently, the group ofMascareñas et al., exploited the pres-
226ence of 2-quinolinecarboxylate ligands in the ruthenium complexes
227for the introduction of different cellular targeting appendages
228(Fig. 2, complexes 6–8), such as phenyl-phosphonium groups that
229may accumulate in mitochondria [51]. It is well known that triph-
230enylphosphonium cations (TPP), because of exhibiting both a pos-
231itive charge delocalized over three phenyl groups and a large
232hydrophobic surface area, are able to accumulate in the mitochon-
233drial inner membrane (IMM) driven by the membrane potential of
234this organelle [52]. The authors demonstrated that despite the func-
235tional complexity of mitochondria, it was possible to accumulate
236active ruthenium complexes in this organelle by equipping the
237ruthenium ligands with suitable arylphophosnium-type of delivery
238vectors. For the visualization of the metal complexes, one of the
239phenyl substituents of the TPP was replaced by a methylenepyrene
240group resulting in a pyrene-phosphonium fluorescent directing
241vector (complex 7, Fig. 2). Indeed, the presence of the phosphonium
242group in the structure of the quinoline Ru ligand facilitates the
243intracellular accumulation and the mitochondrial localization
244(Fig. 4).
245The presence of the pyrene group was observed to have a syn-
246ergistic effect in the accumulation of the ruthenium complexes in
247the mitochondria, promoting an increased concentration of 7 in
248this organelle up to 6-fold compared to the analog 6. Importantly,
249the ruthenium complex presented a remarkable activity, which
250was not only tested using standard fluorogenic probes, but also a
251caged protonophore 1-(allyloxy)-2,4-dinitrobenzene (13) that
252becomes an active mitochondrial uncoupler (14) only after in situ
253Ru-promoted removal of the allyl protecting group (Fig. 5). Indeed,
254using ruthenium complexes that do not accumulate in the mito-
Scheme 2. (Alloc)–amine protected uncaging mechanism proposed by Meggers and co-workers [49].
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255 chondria, the uncaging reaction is much less efficient. This result
256 demonstrates for the first time that having an artificial catalyst
257 localized in a specific cell organelle can bring important biological
258 advantages, and sets the stage for future strategies for selective,
259 target associated drug activations.
260 In this article [51], the intracellular nature of the reaction was
261 further demonstrated by inductively coupled plasma mass spec-
262 trometry (ICP-MS) studies, which confirmed the presence of rea-
263 sonable amounts of ruthenium in the mitochondria, and by
264 incubating the ruthenium complexes prior to the substrates, to
265 ensure their accumulation inside the cells.
266In early 2017, Volker and Meggers reported a new generation of
267Ru complexes with improved stabilities and excellent catalytic
268potential under bio-relevant conditions, even in blood serum
269[53]. This new series of catalysts also possess a quinoline derived
270ligand, 8-hydroxyquinolinate, in which the introduction of with-
271drawing groups at the position 5 of the aromatic ring gave rise to
272an increment in the catalytic activity (complex 9, Fig. 2).
273All these data confirm that appropriately designed Ru com-
274plexes are able to achieve highly interesting deallylation reactions
275in biologically relevant complex aqueous mixtures and even in liv-
276ing cells, in a bioorthogonal manner and without generating major
Fig. 4. Imaging of the subcellular localization and catalytic activity of ruthenium complex 7 (see Fig. 2). (a) Mitochondrial labeling with tetramethylrhodamine ethyl ester
(TMRE) (red), (b) emission of cells incubated with the ruthenium complex (blue), (c) merging of (a) and (b), (d) fluorescence in cells pre-incubated with 7 after addition of
caged rhodamine 1, (e) merging of (a) and (d), (f) merging of (b) and (d) [51].
Fig. 5. In cellulo (HeLa) chemical rescue of the mitochondrial uncoupler 14 from the caged precursor 13 using ruthenium complex 7. (a) and (b) structures of the probes; (c)
TMRE labeled cells after the incubation with 7 (50 lM); (d) same experiment but with a previous incubation of the cells with ruthenium complex 7 (50 lM) prior to the
incubation of the allylprobe 13 (150 lM); the disappearance of the color indicates an efficient depolarization of the mitochondria; (e) TMRE labeled cells after incubation with
14 (500 lM) [51].
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277 toxicities. The application of this type of ruthenium complexes for
278 other type of reactions might open new, important opportunities in
279 research at the interface between organometallic catalysis and bio-
280 logical and cellular chemistry. In this context, a recent publication
281 by the group of Mascareñas et al., has demonstrated that complex
282 3 can promote Ruthenium-Catalyzed Azide–Thioalkyne Cycloaddi-
283 tions (RuAtAC) in water, at room temperature and in the presence
284 of biomolecules (glutathione, aminoacids, peptides) [54]. The reac-
285 tion is also efficient in phosphate buffered saline (PBS) solution,
286 and in complex biological media such as cell lysates and fetal
287 bovine serum, and even in presence of living bacteria. Importantly,
288 the reaction is mutually compatible with the classical CuAAC, thus
289 providing for tandem bioorthogonal processes [54].
290 2.2. Palladium
291 The use of palladium in biological environments is very appeal-
292 ing because of the well-demonstrated catalytic power of many pal-
293 ladium complexes [55], even in aqueous environments.
2942.2.1. Protein modification
295Pioneering work by the group of Davies et al. [56,57], demon-
296strated that using Pd(OAc)2 together with a 2-amino-4,6-
297dihydroxypyrimidine ligands, commonly used in Sonogashira
298Cross-Couplings in organic solvents [58,59], it is possible to
299achieve Suzuki–Miyaura Cross-Couplings (Scheme 3) [60,61] on
300appropriately functionalized proteins, and in biological buffers. In
301vitro experiments showed that thiols like GSH might have a detri-
302mental influence in the reactions.
303They further explored the Suzuki–Miyaura Cross-Coupling reac-
304tion for the 18F labeling of bacterial protein SBL, reactions that
305required the use of Pd(OAc)2 as palladium source, and some of
306the ligands L1–L4 indicated in Fig. 6 [62]. The same group was also
307able to modify the cell-surface of Escherichia coli by using a Suzuki–
308Miyaura Cross Coupling reaction on genetically ‘‘tagged” aryl
309halide-containing porin channels, created through the incorpora-
310tion of the unnatural amino acid pIPhe into OmpC protein mono-
311mers [63]. Despite the undoubtable success of these pioneering
312findings, these experiments were carried out in vitro or in the
313cell-surface of E. coli, and avoiding the presence of free thiols which
314seem to interfere with the Cross-Coupling reaction.
315It is also remarkable the work of Lin and co-workers in the mod-
316ification of an overexpressed modified ubiquitin (Ub) protein in
317E. coli which incorporates an homopropargylglycine residue
318(HPG), using a Sonogashira Cross Coupling reaction (Scheme 4)
319[64]. They have expanded the application of the Cross-Coupling
320reaction to the surface of mammalian cells, being able to modify
321alkynyl-equipped proteins bound to the cellular membrane
322[65,66]. These achievements meant a step forward on the develop-
323ment of metal-promoted chemistry in living cells, however, it was
324still limited to modify cell-surface-tethered biomolecules.
325In 2014, the group of Chen et al., reported the use of discrete Pd
326(II) catalysts to achieve chemical protein activations in living cells,
327using a depropargylation or deallylation of caged lysines. In the
328case of the propargylic (proc) systems, the reaction mechanism is
329not completely clear, and could proceed via PdII/IV or Pd0/II cycles
330(Scheme 5) [29].
331The effectivity of the Pd-promoted despropargylation and deal-
332lylation reactions was monitored in vitro using the di-
333propargylcarbamate–rhodamine probe 15 and bis-allylcarbamate
334caged rhodamine (1), which become fluorescent (2) after removal
335of the propargylcarbamate (proc) or allylcarbamate (alloc) pro-
336tecting groups, respectively (Fig. 7). Among all the catalysts tested
337in their report, Pd2(allyl)2Cl2 and Pd(dba)2 resulted the most effec-
338tive for both types of uncaging in 5/95 DMSO/H2O using an
Scheme 3. General mechanism for a Suzuki–Miyaura Cross Coupling [60,61].
Fig. 6. Representation of the Suzuki–Miyaura Cross-Coupling reaction for the 18F labeling of SBL protein with Pd(OAc)2 and the ligands L1–L4 [62].
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339 equimolar ratio Pd/substrate (10 lM) (Fig. 7). Further experiments
340 in vitro using proc-lysine as substrate in PBS buffer, at 37 C and
341 10% Pd loading, afforded reaction yields of 84% with Pd(dba)2
342 and 82% with Pd2(allyl)2Cl2 (Scheme 6).
343Neither of these catalysts were able to efficiently uncage alloc-
344lysine substrates under the same conditions, 26% and 22% yields
345with Pd(dba)2 and Pd2(allyl)2Cl2 respectively. The proc-lysine
346uncaging strategy was used for the chemical rescue of a non-
Scheme 4. Sonogashira Cross-Coupling labeling of a HPG-encoded Ub protein in E. coli [64].
Scheme 5. Mechanisms proposed for the depropargylation reactions promoted by either (a) Pd(II) or (b) Pd0 complexes [29].
Fig. 7. (a) Uncaging reaction of probe 15 promoted by Pd catalysts and (b) Scheme representing a Pd-mediated activation of OspF bacterial enzyme by proc-lysine uncaging
[29].
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347 overexpressed bacterial enzyme phosphothreonine lyase (OspF)
348 within HeLa cells, using Pd2(allyl)2Cl2 as catalyst (Fig. 7) [29].
349 The same authors were also able to modify the cell membrane
350 by inducing cellular aggregation processes controlled by a metal-
351 promoted decaging of suitable modified cell-surface proteins
352 [67]. They metabolically engineered the incorporation of neuramic
353 acid (Neu) caged with proc protecting groups (Neu5Proc) into cell-
354 surface glycans. The palladium mediated bioorthogonal uncaging
355 reaction gives rise to the in situ generation of Neu, that is therefore
356 exposed on cell-surface glycans. In this report, the authors keep
357 using the same palladium catalysts as in previous works, although
358 the best results were obtained using palladium nanoparticles
359(PdNPs). However, the potential of the strategy is somewhat ham-
360pered because these catalysts need to be used immediately after
361being synthetized [67]. Making use of the same type of Pd com-
362plexes, it has also been described the release of intracellular Tyro-
363sine dependent proteins in living cells using genetically encoded
364proteins containing allene caged tyrosines [68].
365The work published by Chen and co-workers represented a very
366important step forward towards the applicability of Pd catalysts to
367control the biological activity of designed proteins in living sys-
368tems. Nevertheless, there are many challenges that remain to be
369addressed, such as knowing the exact palladium species responsi-
370ble for the activity. Complexes like Pd(dba)2 and Pd2(allyl)2Cl2 are
371known to form Pd0 species, clusters and nanoparticles, depending
372on the Pd loading [69–72]. Thus, a detailed study of the stability
373of these complexes and the nature of the real catalysts remains
374to be performed.
3752.2.2. Pd-nanostructured materials
376Bradley and Unciti-Broceta have pioneered the use of palladium
377nanostructures to promote chemical transformations in living set-
378tings. In their initial work, the authors made use of amino-
379functionalised polystyrene microspheres as a support to reduce
380Pd(OAc)2 to Pd0 nanoparticles (PdNPs, 5 nm). These Pd0-
381microspheres were demonstrated to be effective for the uncaging
382of alloc rhodamine 1 even in cellular systems. The protocol consists
383of loading of HeLa cells with the Cy5.5 labeled Pd0-microspheres,
384following by washing steps, and addition of the fluorogenic rho-
385damine probe 1. Analysis of the result by fluorescence microscopy
386revealed that the nanostructured Pd0 were able to achieve the
387desired uncaging.
388The catalytic capabilities of these small Pd0 microspheres were
389also examined in the context of a Suzuki–Miyaura Cross-Coupling
Scheme 6. Proposed general mechanistic scheme for the cleavage of the allyl group
using Pd0 complexes.
Fig. 8. (a) Suzuki–Miyaura Cross Coupling generating a fluorescent product that is located in the mitochondria owing to the presence of the phosphonium group, and (b)
Representation of the Pd0-microspheres used as catalytic systems [28].
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390 between two exogenous substrates (16 and 17, Fig. 8). The phos-
391 phonium moiety was purposely introduced in one of the reactants
392 to achieve the transformation in the mitochondria surroundings
393 [28]. While the result suggests the viability of the coupling reac-
394 tion, further studies to confirm that this type of bimolecular trans-
395 formations is taking place in the interior of living cells are certainly
396 necessary. Moreover, the above reactions involved fixation of the
397 cells after the incubation of the Pd0-microspheres and the sub-
398 strates, which might lead to artefacts or over-interpretations,
399 because, after fixation, the cell membranes are permeable [73].
400 Therefore, an unambiguous confirmation of the intracellular nature
401 of these reactions would be desirable.
402 These Pd0-microspheres where further studied for other unca-
403 ging processes, such as for an extracellular activation of 5-
404 fluorouracil (5FU), from protected allyl, or propargyl derivatives.
405 The palladium-promoted release of this product triggers the apop-
406 tosis of the cells [74]. Using a related uncaging strategy promoted
407 by Pd0 microspheres it is also possible to release the anticancer
408 agent vironosat in cellular cultures [75].
409 Some of these studies were also translated to zebrafish. Insert-
410 ing the palladium-microspheres in their yolk-sac, the authors were
411 able to observe an increase in the fluorescence after incubation
412 with the fluorogenic probe 15 [76]. These results should be taken
413 with caution as some alternative studies have shown that the
414 probe might be partially hydrolyzed in the fish [33].
415 It has also been demonstrated that the Pd0-nanoparticles (9.2 ±
416 1.5 nm) could also be supported onto a modular polymeric support
417 (9.9  7.5 mm). These supported Pd0-nanoparticles were capable
418 of inducing depropargylation of fluorogenic probes as 15, and also
419 promote the formation of bis-aryl BODYPY fluorophores and the
420 anticancer agent PP-121 (Fig. 9) by means of Suzuki–Miyaura cross
421 coupling reactions [77].
422 It has also been shown that it is possible to modify Pd0 micro-
423 spheres with the cyclic peptide cRGDfE, an appendage that allows
424 an specific uptake by brain cancer cells [78]. In this article, Bradley
425 and collaborators also reported the first example of a dual catalytic
426process in which these cRGDfE-functionalized Pd0 microspheres
427were able to promote the generation of 5FU using an uncaging pro-
428cess, and at the same time promote the synthesis of the anticancer
429agent PP-121 via a Suzuki–Miyaura Cross-Coupling of two benign
430precursors. Therefore, they are able to generate two different drugs
431in a dual manner. The authors support the formation of both prod-
432ucts in living cells by checking the decrease in cellular viability in
433the presence of the precursors of both products, and the Pd0 micro-
434spheres, whereas in the cases where one of the components is
435missing, the cell viability was not affected.
436In their more recent publication about bioorthogonal reactions
437promoted by palladium catalysts, Bradley et al., presented two
438homogeneous tagged carbene-based palladium(II) catalysts conju-
439gated to a cell-penetrating peptide [79]. These catalysts promoted
440the deprotection of the rhodamine probe 15 inside PC-3 cells. How-
441ever, the use of fixed cells advises to be cautious in the interpreta-
442tion of the results.
443Overall, the work by Unciti-Broceta and co-workers have nicely
444demonstrated the applicability of Pd0 containing microspheres for
445the promotion of transformations in biological settings. In several
446of the reports, the large size of the beads suggest that the reactions
447are indeed taking place in the extracellular matrix.
448Other examples on the applicability of palladium catalysts for
449depropargylation reactions in living settings have been recently
450reported by Weissleder and co-workers [80]. The authors made a
451meticulous analysis of the performance of discrete Pd catalysts
452in vitro under biologically relevant conditions, for the uncaging of
453proc protected rhodamine 15 and the alloc derivative 1. Removal
454of propargylic protecting group (proc) was 37% less efficient than
455the cleavage of the alloc group. They also identified that electron
456deficient ligands like tri-2-furylphosphine (TFP) are particularly
457effective to generate reactive Pd0 species under biological compat-
458ible conditions, as TFP readily dissociates from the coordinating
459sphere of the metal. The authors demonstrated that PdCl2(TFP)2
460(19, Fig. 10) is reasonably efficient after 12 h of pre-incubation in
461Hank’s Balanced Salt Solution (HBSS), however, they observed that
Fig. 9. Suzuki–Miyaura Cross Couplings using polymeric supported palladium nanoparticles of (a) bis-aryl BODIPY fluorophores, and (b) anticancer agent PP121 [77].
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462 TFP and Cl ligands suffer dynamic ligand exchange processes in
463 biological complex media. Thus, in order to improve catalyst stabil-
464 ity and delivery, they encapsulated the precatalyst 19 in a poly-
465 meric nanoformulation based on polylactic acid-co-glycolic acid
466 (PLGA) and polyethylene glycol–poly lactic acid-co-glycolic acid
467 (PLGA–PEG). After nanoprecipitation, the resulting nanoparticles
468 resulted quite effective in the above deprotection reactions, and
469 were even tested in vivo using mice as animal model, with promis-
470 ing results [80].
471 Finally, it is worth to comment that there have been also some
472 reports on the use of fluorogenic probes for the detection of palla-
473 dium in cellular contexts, albeit the focus of these studies is not in
474 the catalytic activity [81–84].
475 Overall, we can state that palladium is a powerful metal to
476 promote bioorthogonal catalytic transformations in biological
477 and cellular contexts. In many cases the metal has been used in
478 a nanostructured form, which seems to lead to better results.
479 Caution must be used on concluding that the reactions are taking
480 place inside the cells, particularly when using fixation techniques
481 [28,74,79]. The types of reaction so far studied have been essen-
482 tially restricted to the uncaging of allyl or propargyl protected
483 probes, albeit some isolated examples of Suzuki type of couplings
484 have been also claimed. Considering the enormous potential of
485 palladium complexes in organometallic catalysis, in the near
486 future we should see further biological applications of palladium
487 for promoting other type of reactions in biological contexts. The
488 current knowledge on cell uptake, complex stability and
489structure/toxicity properties of palladium complexes is yet very
490limited, and therefore further studies on these matters are clearly
491needed.
4922.3. Copper
493The paradigm of bioorthogonal reactions that can be achieved
494in aqueous media is the Copper catalyzed Azide–Alkyne Cycloaddi-
495tion (CuAAC, Scheme 1), discovered by the groups of Sharpless and
496Fokin, and Meldal, in 2002 [19,20].
497The reaction, typically promoted by a Cu(II) source, copper
498ligands, and ascorbate as reductant, presents very good reaction
499kinetics, high selectivity, and excellent bioorthogonality, and has
500been extensively used in chemical and cell biology. In comparison
501with other metal-catalyzed biorthogonal transformations, is the
502one leading to higher reaction rates.
503However most of the ‘‘in cellulo” applications have been limited
504to the modification of cell surface proteins and glycans, and mainly
505in bacteria. Its use inside livings cells has been precluded in part by
506the well-known toxicity of copper and ascorbate, which can gener-
507ate reactive oxygen species (ROS) [85]. The employment of water-
508soluble tris(triazole) ligands such as tris-(hydroxypropyltriazolyl
509methyl)amine (THPTA), bis[(tert-butyltriazoyl)methyl]-[(2-carbox
510ymethyltriazoyl)methyl]-amine (BTTAA), or tris[(1-benzyl-1H-1,2,
5113-triazol-4-yl)methyl]amine (TBTA) for Cu(I) (Fig. 11) both
512accelerate the cycloaddition and decrease the redox side reactivity
513[86–88].
Fig. 11. General representation of a CuAAC reaction and some stabilizing ligands for Cu(I).
Fig. 10. Schematic representation of the formation of nanostructures from pre-catalyst 19 and PLGA-PEG [80].
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514 2.3.1. Discrete copper complexes for achieving CuAACs in cellular
515 settings
516 The CuAAC has been very scarcely used inside living cells, prob-
517 ably because obtaining good reactivity requires relatively large
518 amounts of copper, which can be cytotoxic. The pioneering studies
519 on the use of the CuAAC in biological compatible settings were car-
520 ried out by Link and Tirrell in 2003 [89]. In this work, the authors
521 describe the labeling of cell surface proteins of E. coli, using CuSO4
522 as copper source and Tris(2-carboxyethyl)phosphine hydrochloride
523 (TCEP) as reducing agent. Later on, they reported an increase in the
524 labeling efficiency by changing the Cu catalyst to CuBr [90]. In
525 2006, they carried out experiments in mammalian cells that
526 included the metabolic incorporation of HPG and a subsequent
527 CuAAC reaction of the resulting proteins with fluorogenic azides.
528 In these experiments, CuSO4 was used as Cu source, TCEP as reduc-
529 ing agent and cells were fixed before the CuAAC reaction [91].
530 The group of Chen has used the CuAAC reaction for the modifi-
531 cation of a periplasmic pH-responsive acid-chaperone HdeA in
532 E. coli [92]. Therefore, they were able to modify HdeA with the
533 incorporation of (Ne(((1R,2R)-2-azidocyclopentyloxy)carbonyl)-l-l
534ysine) (20), and the resulting proteins can be engaged in a CuAAC
535coupling with a naphthalimide dye (4-N,N-dimethylamino-1,8-na
536phthalimide, 21) (Fig. 12). For these experiments the use 1:5 ratios
537of CuSO4:BTTAA, and sodium ascorbate (NaAsc) as reducing agent.
538These experiments were reproducible in BHK-21 mammalian cells
539expressing the HdeA protein on the cell surface. With this tech-
540nique, it was possible to explore the extracellular pH of bacterial
541or mammalian cells under stressful conditions or during pathogen-
542esis, in a non-invasive fashion.
543Later on, the same group demonstrated that it is possible to
544retarget an azide containing periplasmic protein HdeA to the bacte-
545rial cytosol (Cyto-HdeA) of E. coli and that it can be engaged in a
546CuAAC reaction [93].
547The group of Ting pioneered a powerful alternative to the clas-
548sical CuAAC that has allowed for higher reaction rates and reduced
549side toxicity. The strategy is based on the use of azides containing
550pyridine groups to favor the interaction of the azide with the cop-
551per complex, and therefore decrease the entropic barrier of the
552intermolecular annulation. Therefore, using picolyl azides instead
553of conventional non-chelating azides, they achieved efficient annu-
Fig. 12. Representation of the modification of protein HdeA, after incorporation of the non-natural amino acid 20 using genetic expansion methods, and subsequent CuAAC
reaction with a pH sensitive, alkyne-equipped fluorophore [92].
Fig. 13. Derivatization of pycolyl-azide modified proteins with a terminal pycolyl azide probe and CuAAC annulation with alkynes. Reproduced by permission [26]. Copyright
2012, Wiley-VCH.
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554 lations with modified proteins on the surface mammalian living
555 human embryonic kidney (HEK) cells. The pycolyl azides can also
556 be incorporated into membrane proteins using enzymatic pro-
557 cesses, and then annulated with tagged alkynes using a
558 chelation-assisted CuAAC (Fig. 13) [26].
559 Inspired by this work, the group of Taran and co-workers,
560 designed alternative azides bearing copper-chelating bis(triazole)
561 moieties (22) which allow the formation of azide copper com-
562 plexes (23) (Fig. 14) that react almost instantaneously with alkynes
563 under diluted conditions and in complex media [94]. The technol-
564 ogy allowed to achieve a CuAAC even inside HUH-7 cells. The
565authors used cell fixation techniques after the CuAAC reaction in
566preparations for co-localization studies.
567Recently, Cai and co-workers demonstrated that linking copper
568tris(triazole) ligands to cell penetrating peptides favors the cell
569internalization and also the intracellular reactivity (Fig. 15) [95].
570Using these ligands, they demonstrated the viability of achieving
571CuAAC reactions to modify cellular proteins incorporating HPG
572(Fig. 15c). However, the efficiency of the reaction is modest, par-
573ticularly in the cytoplasm, in part because of the presence of mil-
574limolar concentration of GSH, which is known to inhibit the
575CuAAC.
Fig. 14. Chelating azides (22) used by Taran and coworkers to form N3–Cu complexes (23) to promote the CuAAC [94].
Fig. 15. (a) Tris(triazole) ligand coupled to a cell penetrating peptide employed by Cai and co-workers; (b) biotinylated-azide (biot-N3) used as annulation partner; (c) (i)
representation of the CuAAC to modify proteins containing HPG, in OVCAR5 cells, and subsequent labeling with avidin–FITC (Fluorescein isothiocyanate) and (d) Imaging of
cells after CuAAC reaction, fixation and interaction with Avidin–FITC (green channel) [95].
Scheme 7. Representation of a CuAAC reaction of small molecules promoted by E–CU–NPs to make a drug. The reaction can be achieved in the extracellular medium and
in vivo in zebrafish [96].
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576 2.3.2. Copper nanostructures
577 A couple of recent reports highlight the viability of running
578 CuAAC of exogenous substrates in cellular settings using copper
579 nanostructures. Bradley et al., were able to construct copper
580 nanoparticles (CuNPs, 51.2 ± 4.2 nm) embedded within a poly-
581 meric support, in a similar way to that previously used by the
582 group for assembling palladium microspheres (E–Cu–NP; 160 ± 1
583 0 lm, Cu content 0.34 ± 0.02 lmol Cu/mg resin). The authors
584 demonstrated that these supported E–Cu–NPs promoted the reac-
585 tion of a pro-fluorophore (azide–coumarin) with a small molecule
586 alkyne in the presence of living cells [96]. They also reported the
587 CuAAC of two inert components (25 and 26) to make a triazole
588 cytotoxic anticancer agent derived from Combretastatin (27)
589 (Scheme 7). Importantly, the reaction takes place in the extracellu-
590 lar medium. They also report the in vivo implantation of the nanos-
591 tructures in a zebrafish model and the generation of an active
592 fluorophore by means of the designed CuAAC.
593 Zimmerman et al. have recently demonstrated that Cu-
594 containing organic nanoparticles (Cu–MONPs) are able to catalyze
595 the CuAAC reaction with high efficiency and turnover, not only in
596 water, but also in intracellular settings, both in bacteria and mam-
597 malian cells [97]. The Cu–MONPs were prepared using a Cu(II)-
598 mediated intramolecular cross-linking of aspartate-containing
599 polyolefins in water. The authors demonstrated the efficiency of
600 the reaction using as fluorogenic probe a 3-azido-7-
601 hydroxycoumarin which upon reaction with p-ethynylanisole
602 leads to a highly fluorescent product (Fig. 16). The strategy made
603 possible to selectively synthesize inside cells compounds that
604 otherwise might be difficult to deliver.
605Overall, we can conclude that the CuAAC can be successfully
606applied for tagging genetically/modified proteins on the cell sur-
607face, particularly in bacteria. Achieving the reaction inside living
608cells is much more difficult, especially when using two small mole-
609cules reacting partners. The use of chelating azides seems to be the
610more appropriate tactic to achieve reasonable rates and avoid tox-
611icities, albeit the requirement of copper chelation compromises the
Fig. 16. (a) Representation of the Cu–MONP and (b) cell imaging after incubation with the alkyne and azide probes (100 lM each) in mammalian cells (i) without Cu–MONP
and (ii) with Cu–MONP (500 nM) in NCI-H4660 cells, after 2 h; and (iii) without Cu–MONP and (iv) with Cu–MONP in MDA–MB-231 cells and (c) scheme of the CuAAc
reaction. Adapted with permission from [97]. Copyright 2016 American Chemical Society.
Scheme 8. Proposed catalytic mechanism of gold(III) mediated hydroarylation to
give fluorescent coumarins [109].
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612 turnover of the catalytic process. Thus far, the best results for cou-
613 pling a small azide with an alkyne in intracellular settings are
614 those reported by Zimmerman et al. using Cu–MONPs. Considering
615 the enormous effect of the coordinating ligands in the stability,
616 reactivity, and toxicity of the copper complexes, one can foresee
617 that novel ligands might provide redox stable Cu(I) complexes that
618 could cross cell membranes efficiently, and therefore promote
619 intracellular CuAAC reactions in an effective way.
620 2.4. Gold
621 Gold complexes have been broadly studied in bioinorganic
622 chemistry and chemical biology for their bioactivity, mainly as
623 anticancer agents. Specially, cyclometallated gold(III) complexes
624 have been shown to elicit interesting pharmacological responses.
625 Complexes featuring CN, CNN and CNC-type of ligands have been
626 studied as protein inhibitors, DNA binders as well as promotors
627of intracellular redox damage [98,99]. Albeit less studied, gold(I)
628complexes with thiol, phosphine or NHC ligands have been also
629identified as anticancer agents [98].
630However, the development of bioorthogonal transformations
631promoted by gold complexes is still in a very early stage. Indeed,
632the whole field of gold organometallic catalysis is quite young,
633since it was not until recently that the reactivity of gold ions was
634considered relevant [100–107]. The reactivity of Au(I) and Au(III)
635complexes is associated to their carbophilicity, in particular to
636the ability of these metals to coordinate and activate unsaturated
637bonds.
638Of course, most reactions catalyzed by gold complexes have
639been reported in organic solvents, albeit some isolated transforma-
640tions in aqueous media have also been described [108]. The trans-
641lation of gold catalysis to biological media and cellular settings
642does not seem obvious, however there have been several reports
643on the development of sensing probes for gold ions in cellular envi-
Fig. 17. (a) FRET probe activated by an Au3+ promoted oxacyclization, (b) imaging of N2A cells treated with probe 28 (50 lM) only (i–iv) and the probe 28 for 30 min followed
by AuCl3 (250 lM) for 1 h at 37 C (v–viii): images observed through: green channel (i) and (v) (500–575 nm); red channel (576–700 nm) (ii) and (vi); bright field images (iii)
and (vii) and merged images (iv) and (viii). Scale bar: 10 lm. Adapted with permission from [110]. Copyright 2014 American Chemical Society.
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644 ronments, mainly Au(III) salts, that rely on gold-promoted
645 reactions.
646 In 2010, Kim and co-workers present some data on the viability
647 of using a gold-promoted cyclization of designed alkynyl probes to
648 provide fluorescent coumarin products (Scheme 8), however the
649 cell biology part of manuscript is presented in a very preliminary
650 way [109].
651 In 2014, Ahn and co-workers reported another strategy for sens-
652 ing gold salts in cells based on a gold(III)-promoted oxa-cyclizations,
653 with concomitant ring opening of a rhodamine-lactamring (28). The
654sensing system included a donor dye derived from 1,8-
655naphthalimide that generates a fluorescence resonance energy
656transfer (FRET) process with the rhodamine acceptor (29)
657(Fig. 17). The authors demonstrated that the probe can be used to
658detect gold salts purposely added to cells previously incubatedwith
659the alkyne precursor [110].
660Recently, Tanaka and co-workers reported the development of a
661Glyco–Au(III) complex that appears to be able to promote a gold-
662catalyzed reaction in live mice. This Au(III) complex possess a 7-
663diethylaminocoumarin linked to awater compatible cyclometalated
Fig. 18. (a) Au(III) cyclometallated complex 30 used in the studies; and (b) amide bond formation by alkynyl-ester activation in the mice liver, and intestine promoted by the
conjugates Glyco–Au (Sia) and Glyco–Au (Gal) respectively. (Glycans, Sia = a(2 ? 6)Disialo and Gal = galactosyl.) Reproduced by permission [111]. Copyright 2017, Wiley-
VCH.
Fig. 19. Role of the GSH on the assistance/inhibition on the Au-mediated alkynyl-ester activation. Reproduced by permission [112] Copyright 2017, Wiley-VCH.
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664 Au(III) complex via a short PEG linker (30, Fig. 18a). This conjugate
665 undergo a rapid translocation to target organs (i.e., liver, Glyco–Au
666 (Sia); intestine, Glyco–Au (Gal)) thanks to an interaction with
667 asparagine-linked glycans (N-glycans), and the resulting structures
668 are capable of promoting an amidebond formationbetweenfluores-
669 cent propargyl ester probes andnearby surface-protein amines (e.g.,
670 lysine side chains) (Fig. 18b) [111]. Despite themanuscript does not
671 provide details on the catalytic part of the work, and lacks controls
672 on the in vitro activity of the complexes, the work represents one
673 of the first applications of an Au(III) catalytic complex in live mice,
674 and thus opens new avenues on the potential applications of metal
675 catalysis in biological research.
676 More recently, Unciti-Broceta and co-workers, described the
677 preparation of gold nanoparticles (AuNPs, 30 nm) supported
678 within a PEG-grafted low-cross-linked polystyrene matrix (75
679 lm), and their use for promoting the removal of propargyl protect-
680 ing groups of a fluorogenic rhodamine [112]. It was possible to
681 carry out the reaction in serum-free biological medium. This Au–
682 resin was also successfully tested in cell cultures media, albeit
683 the transformations take place in the extracellular matrix; and
684 even in vivo, using zebrafish as animal model.
685 The mechanistic studies carried out by the group suggest that,
686 under physiological conditions, the deprotection reaction involves
687 the activation of the alkyne by the gold surface, and the nucle-
688 ophilic cooperative action of gold-tethered GSH. At higher concen-
689 trations of GSH, the reaction does not work, because the gold
690 surface is fully packed with GSH molecules which inhibit the
691 approach of the alkynes to the gold surface (Fig. 19).
692 Despite the progress in gold-promoted bioorthogonal reactions
693 in biological media is yet weak, and the biological applications of
694 gold catalysis are in their infancy, the distinctive reactivity of gold
695 species with respect to other metals suggest that we will see soon
696 new and relevant advances in the field.
697 2.5. Iridium
698 Most studies on the biological uses of Iridium organometallic
699 complexes have been focused on the area of bioinorganic and
700 medicinal chemistry, as well as in the development of imaging
701 agents. The use of iridium complexes as catalysts in biological set-
702 tings has been much more limited. The group of Sadler et al. has
703 pioneered interesting studies on the viability of using organoirid-
704 ium complexes as catalytic drugs inside cells, mainly for the
705controlled alteration of the NADH/NAD+ equilibrium [42,43,113–
706115]. They have designed iridium complexes which are capable
707of generating H2O2 by catalytic hydride transfer from the coen-
708zyme NADH to oxygen. Some of these organoiridium complexes
709have even shown interesting anticancer potential owing to this
710ability to change the redox status of the cell.
711Recently, the group of Do et al., developed iridium complexes
712which are able to promote aldehyde reductions in cell culture,
713through hydride transfer processes mediated by NADH [116]. The
714best results were obtained using iridium chloride complexes
715equipped with pentametylcyclopendienyl groups and chelating
716ligands like N-phenyl-2-pyridinecarboxamidate (Fig. 20a, com-
717plexes 31–33). These iridium catalysts are fairly stable under phys-
718iological conditions, tolerating moderate concentrations of
719biological nucleophiles such as GSH. The complexes are able to
720promote transfer hydrogenation processes in a versatile bioorthog-
721onal way, which can be useful for the catalytic detoxification of
722disease-causing agents. The reduction processes can be monitored
723by fluorescence microscopy by using substrates such as BODIPY–
724CHO (34), which upon reduction to its alcoholic form (BODIPY–
725OH, (35)) experiment a change in the intensity of the fluorescence
726emission (Fig. 20b) [117].
727The chemistry of Iridium catalysts in living cells has been essen-
728tially confined to hydride transfer modifications. Thus, the real
729challenge now lies on the translation to the biological medium of
730other type of iridium-mediated processes, including processes
731involving CAH activations.
7322.6. Iron
733In contrast to Pd, Ru, Au or Ir, iron is a transition metal very
734commonly used by nature, also for catalytic processes, but mainly
735in redox like transformations. The use of iron complexes to pro-
736mote non-natural intracellular transformations with exogenous
737substrates has been rather limited. Indeed, to the best of our
738knowledge, there is only one example, published by Meggers
739et al., describing the use of an iron(III) 5,10,15,20-tetraphenyl-21
740H,23H-porphine (TPP) complex [Fe(TPP)]Cl (36) to promote the
741reduction of the Rhodamine–bisazide 37 to rhodamine 110 (2)
742(Fig. 21) in HeLa cells [118]. The reaction can be monitored by flu-
743orescence, owing to the increase in the emission of green light of
744the reduced probe. This experiment was also performed in vivo,
745using nematodes and zebrafish as animal models, and it was
Fig. 20. (a) Representation of the Ir(III) catalysts 31–33, the caged fluorophore 34 and the fluorogenic reduced probe 35, and (b) imaging of NIH-3T3 cells treated with (i) 34
(30 lM), (ii) 35 (30 lM), (iii) 34 (30 lM)/31 (20 lM), (iv) 34 (30 lM)/33 (10 lM), (v) 34 (30 lM)/IrCl3 (20 lM), and (vi) 34 (30 lM)/31 (20 lM)/sodium pyruvate (10 mM).
Sodium pyruvate was used to slow down the production of NADH which inhibited the hydride transfer from NADH to 53. Adapted by permission [117]. Copyright 2017,
Wiley-VCH.
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746 possible to observe how the green emission was spread out
747 through the animal bodies. However, the authors later found out
748 that most probably the fluorescence is arising from in vivo meta-
749 bolic reduction of aromatic azides, not by the iron-mediated
750 reduction.
751 3. Artificial metalloenzymes
752 Not surprisingly, the more efficient metal-catalyzed transfor-
753 mations in aqueous and biological media are those promoted by
754 metalloenzymes, natural proteins equipped with metal cofactors
755 in their active site. However, in most of these reactions the metal
756 works either as a Lewis acid or as an electron transfer center,
757 and does not engage in organometallic mechanisms typically
758 found in other types of transition-metal catalysis (oxidative addi-
759 tions, reductive eliminations, migratory insertions. . .) [119].
760 Therefore, along recent years there has been a great interest in
761 the development of metalloproteins that can achieve metal-based
762 transformations which are not present in nature. Most of the work
763 has been carried out in the context of asymmetric synthesis, albeit
764 some preliminary examples on the development of mimetic of nat-
765 ural enzymes capable of working in living environments have been
766 also developed. A number of detailed reviews in the area have been
767 recently published [35–40], and therefore we will not provide a
768 comprehensive review in this topic. Roelfes and co-workers pub-
769 lished several reports on the engineering of non-natural protein
770 catalysts by grafting non-proteinogenic amino acids capable of
771 binding a transition-metals, and therefore provide an active site
772 for different reactions. Thus, they built Bovine pancreatic
773 polypeptide–Cu complexes (bPP–Cu(II)) which are able to pro-
774 mote Diels–Alder and Michael addition reactions in water, with
775enantioselectivities up to 86% [120]. Later, they grafted a new
776active site onto the dimer interface of the protein LmrR by intro-
777ducing bidentate phenanthroline and bipyridine ligands capable
778of binding Cu(II) ions. The resulting metalloproteins allowed to
779improve the enantioselectivity of the Diels–Alder reaction up to
78097% enantiomeric excess (ee) [121]. In 2015 they also achieved
781Friedel–Crafts reactions of indoles, in water, with good enantiose-
782lectivity [122]. One year later, they were able to assemble a metal-
783loenzyme in the context of the LmrR protein, incorporating a
784metal-binding non-proteinogenic amino acid (2,20-bipyridin-5yl)
785alanine (38), using gene expansion techniques. This represented
786the first example of an artificial metalloenzyme with an in vivo
787incorporated unnatural amino acid capable of binding a transition
788metal ion and catalyzing an enantioselective reaction (Scheme 9)
789[123].
790Additional pioneering work on the development of non-natural
791metalloenzymes has been achieved by the group of Arnold, which
792among other advances, has been able to build modified cyto-
793chrome P450 proteins capable of promoting enantioselective
794cyclopropanations [124], and aziridinations of olefins [125]. Fasan
795and co-workers have also nicely contributed in this topic by the
796use of cytochrome P450 variants for the oxidation of sp3 CAH
797bonds [126], and for the amination of sp3 CAH bonds [127].
798The group of Hartwig and co-workers, presented a nice strategy
799for the development of artificial metalloenzymes based on the
800replacement of the native metals of the protein cofactors by noble
801metals [128]. The designed systems elicited a totally different cat-
802alytic activity, and the selectivity of the reaction could be modu-
803lated by using directed evolution approaches. Thus, using heme
804proteins as scaffolds and Fe–porphyrin IX [Fe–PIX] as reference
805for the metal cofactor, they demonstrated that it is possible to
Scheme 9. Representation of the modified LmrR metalloenzyme with an in vivo incorporated ligand 38, and reaction scheme of the benchmark catalytic Friedel–Crafts
reaction between 39 and 40 to obtain 41. Reaction conditions: 9 mol% Cu(H2O)6(NO3)2 (90 lM) loading with 1.25 eq LmrR_LM_X (in monomer) in 20 mM MOPS buffer (pH
7.0), 150 mM NaCl, for 3 days at 4 C [123].
Fig. 21. (a) Fe complex used for the reduction reaction; and (b) iron-catalyzed reduction of the azide 37 to generate fluorescent product 2 [118].
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806 substitute Fe by several noble metals (Fe(Cl)-, Co(Cl)-, Cu-, Mn(Cl)-,
807 Rh-, Ir(Cl)-, Ir(Me)-, Ru(CO)- and Ag-) to give novel type of metal-
808 loenzymes [128]. The methodology employed for the formation
809 of these artificial metalloenzymes involved express directly and
810 purify apo-PIX proteins lacking the entire heme unit, which is
811 reconstituted with the above derived metal cofactors containing
812 metals other than iron in a stoichiometric fashion. The strategy
813 involved minimal media lacking Fe to minimize the bio-synthesis
814 of hemin. This method indeed generated [M]–PIX–proteins with
815 the intact active site and with the cofactors bound at the native
816 PIX-binding site. These artificial metalloenzymes were evaluated
817 for asymmetric CAH insertion and cyclopropanation reactions
818 using carbenes, under biological relevant conditions (10 mM Tris,
819pH 8.0 containing 8 vol.% MeCN) (Fig. 22). In the evaluation of
820these artificial myoglobins ([M]–Myo) as catalysts, they found that
821the [Ir(Me)–PIX] co-factor (42, Fig. 22) exhibited excellent perfor-
822mances with eight myoglobin mutants for both reactions. In the
823CAH insertion reactions were obtained selectivities up to an enan-
824tiomeric ratio (e.r.) of 92:8 and with yields up to 97%. In the cyclo-
825propanations they obtained e.r. up to 91:9 and a trans:cis ratio of
82640:1.
827Further research by the same group has led to improved ther-
828mostable variant of cytochrome P450 from Sulfolobus solfatarius
829(CYP119) containing the cofactor 42. The carbene insertion was
830used again as model reaction. Several mutants from this artificial
831metalloenzyme were studied in a variety of carbene insertion reac-
832tions. In particular, mutants of the P450 enzyme Ir(Me)-CYP119
833containing 42 as cofactor catalyzed insertions of carbenes into
834CAH bonds with excellent yields and up to 98% ee. The quadruple
835mutant of P450 Ir(Me)-CYP119-C317G-L69V-V254L (Ir(Me)-CYP-
836Max) led to further improvements of both kcat and KM, creating
837an enzyme with an efficiency that improved up to 4000-fold (kcat
838= 45.8 min1, KM = 0.17 mM, and kcat/KM = 269 min1 mM1) that
839of the Ir(Me)-CYP119 system [129].
840While most of this work deals with the use of the designed
841enzymes in asymmetric catalysis, preliminary attempts to build
Fig. 22. (a) CAH insertion and, (b) cyclopropanation reactions promoted by [M]–Myo mutants (c) Structure of the co-factor 42 which provides better performance catalyzing
CAH insertion and cyclopropanation reactions [128].
Scheme 10. Representation of the biot–Sav strategy for the formation of artificial
metalloenzymes.
Fig. 23. Biotinylated complexes derived from Ir (45 [130,131] and 46 [132]), Pd (47 [133]) and Ru (48 [134]), used for the assembly of metalloenzymes by Ward and co-
workers.
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842 non-natural enzymes that can work in living environments are
843 starting to be published. Perhaps the more relevant study has been
844 recently reported by Ward and co-workers. This group has been
845 pioneered on the use of biotin–streptavidin (biot–Sav, Scheme 10)
846 interactions to build a variety of metalloenzymes equipped with
847 metal catalysts [40]. Many of these hybrids perform very well in
848 different type of transformations, including hydrogen transfer
849 reactions by the incorporation of a d6-piano chair complexes
850 within a host protein, [Cp⁄Ir(biot-p-L)Cl] (45) [130,131] and
851 [(Cp⁄-biot)Ir(L^L)Cl] (46) [132] giving rise to artificial transfer
852 hydrogenases (ATHase). The biot–Sav strategy has also been
853 applied to other bioorthogonal reactions such as the Suzuki–
854 Miyaura Cross Coupling (using biot–Pd 47 as cofactor), affording
855 an artificial Suzukiase for the synthesis of enantioenriched binaph-
856 thyls [133]. They have also built ruthenium-based metalloenzymes
857 using biot–Ru 48, which were able to promote a metathesis reac-
858 tion in the periplasm of E. coli (Fig. 23) [134].
859 The group has demonstrated that embedding an organometallic
860 Iridium 45 complex within a host protein allows to overcome the
861 poisoning of transition metal in living cells by the presence of thi-
862 ols, mainly present in the form of GSH. The catalytic power of the
863 Sav-complex with iridium complex 45 was evaluated ex cellulo,
864 under different conditions, in the absence and in the presences of
865 the Sav mutant, cell lysates and E. coli culture and in the presence
866 of GSH neutralizing agents. While the free complex is capable to
867 promote the racemic conversion of 6,7-dimethoxy-1-methyl-3,4-
868 dihydroisoquinoline (49) to salsolidine (50) with excellent yields,
869 the presence of the mutant of the Sav S112A gave rise to excellent
870 yields and more than 80% ee (Scheme 11) [131].
871With regard to the metathesis reaction with organoruthenium
872complex 48; the authors demonstrated that this species is nearly
873inactive in cellulo, whereas the corresponding wild-type artificial
874metalloenzyme biot–Ru–Savperi endows the cell with metathesis
875activity in the periplasm of E. coli (Fig. 24) [134].
8764. Conclusions and closing remarks
877Achieving organometallic catalytic reactions of exogenous sub-
878strates in the complex aqueous environment of living cells and tis-
879sues is an enormous challenge. While the field is in its infancy,
880there is a steady increase in publications reporting new type of
881transformations in biological media and living cells. Therefore,
882while up to 2010 the reports were mainly limited to copper-
883catalyzed Click-type reactions, and only a few of them referring
884to the inside living cells all, of them up to 20 publications; after
8852010 we have counted around 100 articles dealing with other
886metal-promoted transformations in biological media [30–33].
887Promoting intracellular reactions is particularly difficult owing
888to the presence of a high concentration of components such as thi-
889ols or amines, which can poison the metal and kill the catalytic
890activity. Obtaining practical catalysts also require to deal with
891other issues such as cellular transport and side toxicity. In the
892future, it will be also needed to consider metal speciation, as well
893as analyze turnover and reaction rates inside cells.
894Furthermore, other questions such as catalyst confinement
895within a specific organelle/environment, or the association of the
896catalytic complex with specific targets, remain to be addressed.
897Despite all these difficulties, the enormous possibilities offered
898by organometallic chemistry, mainly because of the ligand vari-
899ability that can be achieved, promises important future develop-
900ments. Until know most of the advances have been essentially
901limited to copper-promoted azide–alkyne annulations, and to
902uncaging reactions triggered by ruthenium or palladium com-
903plexes. There is therefore enormous room for developing other
904type of transformations, such as cyclizations, coupling reactions,
905annulations or CAH functionalizations, reactions that do not occur
906in nature. For instance, in this context, recent work in the CAH
907functionalization of nucleobases in aqueous media might lead to
908future biological applications [135,136].
909Advances in ligand design might lead to good ratios between
910reactivity and biological stability of the metal complexes, and even
911avoid the need to use nanostructure formulations for their deliv-
Scheme 11. Asymmetric reduction promoted by embedded 45 employing the biot–
Sav strategy [131].
Fig. 24. (a) Streptavidin is secreted to the periplasm by fusion to an N-terminal signal peptide from the outer membrane protein A (OmpA); (b) the biotinylated
organoruthenium catalyst binds to the Sav forming the biot-Ru–Savperi; (c) catalytic bio-orthogonal metathesis reaction promoted by the biot-Ru–Savperi metalloenzyme at
the periplasm of E. coli. Adapted with permission from [134], copyright 2017 Nature Publishing Group.
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912 ery. Nanoparticles are not exempt of problems derived from the
913 protein corona effect and endosomal trapping; however, nanotech-
914 nology might also offer attractive opportunities in terms of trans-
915 port, toxicity control and spatio-temporal triggering of the
916 reactivity.
917 The expected progress in the field might therefore lead to
918 important future applications in biological and medicinal
919 chemistry.
920 Advances in this topic might allow for applications of the cat-
921 alytic power of the organometallic complexes in medicinal chem-
922 istry. Additionally, the development of artificial metalloenzymes
923 that can complement natural enzymes and therefore allow the
924 construction of an artificial metabolism is other of the future chal-
925 lenges in the area.
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